retatrutide type 2 diabetes trial dosing as a Novel Treatment for Obesity and Retatrutide Research Concentration Overview |
Description
Wegovy follows a more extended titration schedule over 1620 weeks to reach the 2.4 mg maintenance dose
ELIXA trial included patients with recent cardiovascular event (patients with acute coronary syndrome 180 days before randomization), and although there was no benefit in MACE reduction in lixisenatide treated patients compared to placebo, results revealed cardiovascular safety of lixisenatide in this specific high risk population (38, 40)
They have the most data on semaglutide because its been around longest and used more often than other GLP-1s, the doctors explain
How long would I be on this medication
Continuous support is a cornerstone of the TrimRx philosophy
Behavioural Therapy Programmes Includes CBT-based support for emotional eating, body image, and long-term weight regulation
